Biogen drug Tofersen showed promising results when taken for six months beyond previous trial
An experimental drug for motor neurone disease (MND) has shown signs of slowing the progress of the devastating illness in a landmark trial.
The results provide fresh hope after a phase-three trial of the same drug had previously failed to make a meaningful difference to patient outcomes after six months of treatment.
